These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35363592)

  • 1. CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort.
    Molyneaux PL; Fahy WA; Byrne AJ; Braybrooke R; Saunders P; Toshner R; Albers G; Chua F; Renzoni EA; Wells AU; Karkera Y; Oballa E; Saini G; Nicholson AG; Jenkins RG; Maher TM
    Am J Respir Crit Care Med; 2022 Jun; 205(12):1440-1448. PubMed ID: 35363592
    [No Abstract]   [Full Text] [Related]  

  • 2. CYFRA 21.1 in bronchoalveolar lavage of idiopathic pulmonary fibrosis patients.
    Vercauteren IM; Verleden SE; McDonough JE; Vandermeulen E; Ruttens D; Lammertyn EJ; Bellon H; De Dycker E; Dooms C; Yserbyt J; Verleden GM; Vanaudenaerde BM; Wuyts WA
    Exp Lung Res; 2015; 41(8):459-65. PubMed ID: 26381718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.
    Jenkins RG; Simpson JK; Saini G; Bentley JH; Russell AM; Braybrooke R; Molyneaux PL; McKeever TM; Wells AU; Flynn A; Hubbard RB; Leeming DJ; Marshall RP; Karsdal MA; Lukey PT; Maher TM
    Lancet Respir Med; 2015 Jun; 3(6):462-72. PubMed ID: 25770676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study.
    Maher TM; Oballa E; Simpson JK; Porte J; Habgood A; Fahy WA; Flynn A; Molyneaux PL; Braybrooke R; Divyateja H; Parfrey H; Rassl D; Russell AM; Saini G; Renzoni EA; Duggan AM; Hubbard R; Wells AU; Lukey PT; Marshall RP; Jenkins RG
    Lancet Respir Med; 2017 Dec; 5(12):946-955. PubMed ID: 29150411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokeratin 19 fragment in patients with nonmalignant respiratory diseases.
    Nakayama M; Satoh H; Ishikawa H; Fujiwara M; Kamma H; Ohtsuka M; Sekizawa K
    Chest; 2003 Jun; 123(6):2001-6. PubMed ID: 12796181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational study.
    Niwamoto T; Handa T; Murase Y; Nakatsuka Y; Tanizawa K; Taguchi Y; Tomioka H; Tomii K; Kita H; Uyama M; Tsuchiya M; Emura M; Kawamura T; Arai N; Arita M; Uno K; Yoshizawa A; Uozumi R; Yamaguchi I; Matsuda F; Chin K; Hirai T
    Respir Res; 2021 Jun; 22(1):181. PubMed ID: 34158044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a Novel Biomarker for the Progression of Idiopathic Pulmonary Fibrosis.
    Yeo HJ; Ha M; Shin DH; Lee HR; Kim YH; Cho WH
    Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deep Learning-based Segmentation of Computed Tomography Scans Predicts Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis.
    Thillai M; Oldham JM; Ruggiero A; Kanavati F; McLellan T; Saini G; Johnson SR; Ble FX; Azim A; Ostridge K; Platt A; Belvisi M; Maher TM; Molyneaux PL
    Am J Respir Crit Care Med; 2024 Aug; 210(4):465-472. PubMed ID: 38452227
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias.
    White ES; Xia M; Murray S; Dyal R; Flaherty CM; Flaherty KR; Moore BB; Cheng L; Doyle TJ; Villalba J; Dellaripa PF; Rosas IO; Kurtis JD; Martinez FJ
    Am J Respir Crit Care Med; 2016 Nov; 194(10):1242-1251. PubMed ID: 27149370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating biomarker analyses in a longitudinal cohort of patients with IPF.
    Ebert C; Walsh AM; Sereda L; Wilson CL; Schafer PH; Fischer A; Zhao L; Ramirez-Valle F; Gordon D; Schnapp LM
    Am J Physiol Lung Cell Mol Physiol; 2024 Mar; 326(3):L303-L312. PubMed ID: 38226605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gremlin-1 for the Differential Diagnosis of Idiopathic Pulmonary Fibrosis Versus Other Interstitial Lung Diseases: A Clinical and Pathophysiological Analysis.
    Aoshima Y; Enomoto Y; Muto S; Meguro S; Kawasaki H; Kosugi I; Fujisawa T; Enomoto N; Inui N; Nakamura Y; Suda T; Iwashita T
    Lung; 2021 Jun; 199(3):289-298. PubMed ID: 33770226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum markers of pulmonary epithelial damage in systemic sclerosis-associated interstitial lung disease and disease progression.
    Stock CJW; Hoyles RK; Daccord C; Kokosi M; Visca D; De Lauretis A; Alfieri V; Kouranos V; Margaritopoulos G; George PM; Molyneaux PL; Chua F; Maher TM; Abraham DJ; Ong V; Donovan J; Sestini P; Denton CP; Wells AU; Renzoni EA
    Respirology; 2021 May; 26(5):461-468. PubMed ID: 33336433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers.
    Raghu G; Richeldi L; Jagerschmidt A; Martin V; Subramaniam A; Ozoux ML; Esperet CA; Soubrane C
    Chest; 2018 Dec; 154(6):1359-1370. PubMed ID: 30526970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis.
    Vuga LJ; Tedrow JR; Pandit KV; Tan J; Kass DJ; Xue J; Chandra D; Leader JK; Gibson KF; Kaminski N; Sciurba FC; Duncan SR
    Am J Respir Crit Care Med; 2014 Apr; 189(8):966-74. PubMed ID: 24628285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic Biomarkers of Survival in Idiopathic Pulmonary Fibrosis.
    Oldham JM; Huang Y; Bose S; Ma SF; Kim JS; Schwab A; Ting C; Mou K; Lee CT; Adegunsoye A; Ghodrati S; Pugashetti JV; Nazemi N; Strek ME; Linderholm AL; Chen CH; Murray S; Zemans RL; Flaherty KR; Martinez FJ; Noth I
    Am J Respir Crit Care Med; 2024 May; 209(9):1111-1120. PubMed ID: 37847691
    [No Abstract]   [Full Text] [Related]  

  • 16. Fibroblast activation protein and disease severity, progression, and survival in idiopathic pulmonary fibrosis.
    Prior TS; Hoyer N; Davidsen JR; Shaker SB; Hundahl MP; Lomholt S; Deleuran BW; Bendstrup E; Kragstrup TW
    Scand J Immunol; 2024 Sep; 100(3):e13392. PubMed ID: 38849304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
    Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
    Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Turnover of type I and III collagen predicts progression of idiopathic pulmonary fibrosis.
    Jessen H; Hoyer N; Prior TS; Frederiksen P; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB; Shaker SB
    Respir Res; 2021 Jul; 22(1):205. PubMed ID: 34261485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis.
    Akiyama N; Hozumi H; Isayama T; Okada J; Sugiura K; Yasui H; Suzuki Y; Kono M; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Nakamura Y; Suda T
    Respirology; 2020 Jul; 25(7):743-749. PubMed ID: 31597225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis.
    Prasse A; Probst C; Bargagli E; Zissel G; Toews GB; Flaherty KR; Olschewski M; Rottoli P; Müller-Quernheim J
    Am J Respir Crit Care Med; 2009 Apr; 179(8):717-23. PubMed ID: 19179488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.